Phase 1 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 75 years old on the day they sign the consent form
- People who are able to give voluntary consent, understand what the study involves, and are willing to follow all study procedures
- People who have been confirmed through laboratory testing to have non-small cell lung cancer (a specific type of lung cancer) after surgery, with a clear tumour type identified in a pathology report
Who may not be able to join:
- People whose tumour has a specific gene change known as an EGFR mutation
- People whose cancer has been diagnosed as small cell lung cancer, a mixed tumour containing small cell components, large cell neuroendocrine carcinoma, or sarcomatoid tumour (confirm with trial site)
- People who have previously received more than 4 cycles of chemotherapy after surgery, or any cancer treatment before surgery
- People who have had major surgery within 4 weeks before joining the trial, or who are expected to have major surgery during the study (not including procedures to place a vascular access device)
- People who have used Chinese herbal medicines intended to treat cancer within 14 days before joining the trial
- People who have received growth factor support therapy or a blood transfusion within 14 days before joining the trial
- People who have previously been treated with certain immune-based cancer therapies, including anti-PD-1, anti-PD-L1/2, anti-CD137, or CTLA-4 treatments, or similar drugs
- People who have a serious active or ongoing infection that requires treatment with antibiotics or other anti-infective medicines within 2 weeks before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiaorong Dong, Dr., Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phone: 86-15040223137
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
PK equivalence
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.